# US 2015/0147358 A1 · Methods for modulating immune responses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147358 A1
- Document ID: US20150147358A1
- Status: Published application
- Kind: A1
- Application number: 14/614,911
- Filed: 2015-02-05
- Published: 2015-05-28
- Earliest claimed: 2007-01-17
- Assignees: Stemnion, Inc.
- Applicants: Stemnion, Inc.
- Inventors: Richard A. Banas; Catherine J. Trumpower; Vivienne S. Marshall
- Web page: https://patentgrep.com/patent/US20150147358A1

## CPC

- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 38/1709: {from mammals}
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/21: Interferons {[IFN]}
- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/10: characterised by the cell type used
- A61K 40/46: Viral antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C12N 5/0634: {Cells from the blood or the immune system}
- C12N 2502/025: extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.

## Claims

### Claim at position 1

-18. (canceled)

### Claim 19

A method for down-regulating the immune response a transplanted allogeneic graft tissue exhibits when it is exposed to host tissue in a subject receiving the transplant, the method comprising the step of simultaneously transplanting the graft tissue and a purified population of CD117-negative Amnion-derived Multipotent Progenitor (AMP) cells into the subject such that the AMP cells down-regulate the immune response exhibited by the graft tissue when it is exposed to host tissue.

### Claim 20 (depends on 19)

The method of claim 19 wherein the transplanted allogeneic graft tissue is selected from the group consisting of a solid organ and bone marrow.

### Claim 21 (depends on 19)

The method of claim 19 wherein the immune response exhibited by the graft tissue is graft-versus-host disease (GVHD).

### Claim 22

A method for improving engraftment of an allogeneic graft tissue transplanted into a subject in need thereof, the method comprising the step of simultaneously transplanting the graft tissue and a purified population of CD117-negative Amnion-derived Multipotent Progenitor (AMP) cells into the subject such that the AMP cells down-regulate a graft-versus-host response following transplant such that improved engraftment of the allogeneic graft tissue results.

### Claim 23 (depends on 19)

The method of claim 19 wherein the transplanted allogeneic graft tissue is selected from the group consisting of a solid organ and bone marrow.